What's Happening?
Roche has announced promising results from a phase 3 trial of its experimental KRAS G12C inhibitor, divarasib, which demonstrated improved efficacy over existing therapies from Amgen and Bristol Myers Squibb. The Krascendo 1 study compared divarasib directly
with Amgen's Lumakras and BMS's Krazati in patients with previously treated KRAS G12C-mutated non-small cell lung cancer (NSCLC). According to Roche, divarasib was more effective in delaying disease progression and extending survival. The trial results suggest divarasib has 'best-in-class potential' and will be used for regulatory filings. While full results are pending presentation at a future cancer congress, Roche reported that divarasib achieved a statistically significant improvement in progression-free survival and overall survival compared to its competitors. The company is also conducting additional trials, Krascendo 2 and Krascendo 3, to explore divarasib's use in combination with other treatments and in earlier-stage disease.
Why It's Important?
The development of divarasib represents a significant advancement in the treatment of KRAS G12C-mutated NSCLC, a challenging cancer subtype. The success of divarasib could establish it as a new standard of care, potentially improving outcomes for patients with this genetic mutation. The KRAS G12C inhibitors market, initially expected to generate substantial sales, has faced challenges such as narrow patient populations and drug resistance. Divarasib's superior efficacy could help overcome these barriers, expanding the market and providing a more effective treatment option. This development also highlights the ongoing innovation in oncology, as pharmaceutical companies continue to target previously 'undruggable' cancer mutations.
What's Next?
Roche plans to use the trial results to seek regulatory approval for divarasib, which could lead to its introduction as a new treatment option for KRAS G12C-mutated NSCLC. The company is also conducting further trials to explore the drug's potential in combination therapies and earlier-stage disease, which could broaden its application and impact. The success of divarasib may prompt competitors to accelerate their own research and development efforts in the KRAS inhibitor space, potentially leading to more treatment options for patients.
